BIOMAT Database Logo BIOMAT Database Logo

Crushing of deutetrabenazine tablets limited to individual case. 2021

Jon P Wietholter, and Jenna Sizemore, and Kara Piechowski
West Virginia University (WVU) School of Pharmacy WVU-Medicine Ruby Memorial Hospital Department of Clinical Pharmacy Morgantown, WV.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071057 Tardive Dyskinesia Drug-related movement disorder characterized by uncontrollable movements in certain muscles. It is associated with a long-term exposure to certain neuroleptic medications (e.g., METOCLOPRAMIDE). Tardive Dystonia,Dyskinesia, Tardive,Dyskinesias, Tardive,Dystonia, Tardive,Dystonias, Tardive,Tardive Dyskinesias,Tardive Dystonias
D013607 Tablets Solid dosage forms, of varying weight, size, and shape, which may be molded or compressed, and which contain a medicinal substance in pure or diluted form. (Dorland, 28th ed) Tablet
D013747 Tetrabenazine A drug formerly used as an antipsychotic and treatment of various movement disorders. Tetrabenazine blocks neurotransmitter uptake into adrenergic storage vesicles and has been used as a high affinity label for the vesicle transport system. Nitoman,Xenazine

Related Publications

Jon P Wietholter, and Jenna Sizemore, and Kara Piechowski
On crushing of deutetrabenazine tablets.
August 2021, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
Jon P Wietholter, and Jenna Sizemore, and Kara Piechowski
Crushing buprenorphine tablets.
December 2003, Drug and alcohol review,
Jon P Wietholter, and Jenna Sizemore, and Kara Piechowski
Distribution of crushing strength of tablets.
May 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,
Jon P Wietholter, and Jenna Sizemore, and Kara Piechowski
Drug loss while crushing tablets: Comparison of 24 tablet crushing devices.
January 2018, PloS one,
Jon P Wietholter, and Jenna Sizemore, and Kara Piechowski
[Evaluation of the quality of tablets according to their resistance to crushing].
January 1961, Meditsinskaia promyshlennost' SSSR,
Jon P Wietholter, and Jenna Sizemore, and Kara Piechowski
Crushing tablets, opening capsules: when is it safe?
August 1978, RN,
Jon P Wietholter, and Jenna Sizemore, and Kara Piechowski
"Crushing-strength" of compressed tablets I. Comparison of testers.
March 1968, Journal of pharmaceutical sciences,
Jon P Wietholter, and Jenna Sizemore, and Kara Piechowski
Crushing of dolutegravir fixed-dose combination tablets increases dolutegravir exposure.
September 2018, The Journal of antimicrobial chemotherapy,
Jon P Wietholter, and Jenna Sizemore, and Kara Piechowski
Cystic fibrosis: Does it matter to avoid crushing Elexacaftor/Tezacaftor/Ivacaftor (ETI) tablets?
December 2023, Pediatric pulmonology,
Jon P Wietholter, and Jenna Sizemore, and Kara Piechowski
Determination of the crushing strength of intact tablets using Raman spectroscopy.
August 2008, International journal of pharmaceutics,
Copied contents to your clipboard!